RO-3306, a CCNB1/CDK1 inhibitor, can simultaneously inhibit the activity of both CCNB1 and CDK1 [14], and has previously been shown to suppress tumor-initiating capacity in melanoma by disrupting CDK1-Sox2 signaling [15]. This evidence concerns the gene SOX2 and neoplasm.